Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

NCT03458728 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

31

Enrollment

INDUSTRY

Sponsor class

Stopped no anticipated benefit over available standard therapies

Conditions

Relapsed or Refractory Solid Tumors or Lymphoma in Children
Neuroblastoma
Osteosarcoma
Rhabdomyosarcoma
Ewing Sarcoma

Interventions

DRUG: Copanlisib (BAY806946)

Sponsor

Bayer